Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168344 | 0.77 | ALDH1A1 (0.46) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| Thioxanthene SCHEMBL8717 | 0.76 | ALDH1A1 (0.61) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| Thioxanthene SCHEMBL29398766 | 0.76 | ALDH1A1 (0.61) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL9001277 | 0.74 | CYP1A2 (0.33) | ALDH1A1HPGDKDM4EMAOA | |
| SCHEMBL6754377 | 0.74 | ALDH1A1 (0.37) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL8073109 | 0.74 | HPGD (0.37) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| Thioxanthene SCHEMBL28542371 | 0.74 | ALDH1A1 (0.59) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL18311802 | 0.74 | ALDH1A1 (0.59) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| Thioxanthene SCHEMBL31106427 | 0.74 | ALDH1A1 (0.59) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| Thioxanthene SCHEMBL28751085 | 0.74 | ALDH1A1 (0.59) | ALDH1A1HPGDKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4399200-A1 | (HET)ARYL SUBSTITUTED BISPHENOL COMPOUNDS AND THERMOPLASTIC RESINS | Mitsubishi Gas Chemical Company, Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-4399199-A1 | (HET)ARYL SUBSTITUTED BISPHENOL COMPOUNDS AND THERMOPLASTIC RESINS | Reuter Chemische Apparatebau e.K. (DE) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023038156-A1 | (HET)ARYL SUBSTITUTED BISPHENOL COMPOUNDS AND THERMOPLASTIC RESINS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023036868-A1 | (HET)ARYL SUBSTITUTED BISPHENOL COMPOUNDS AND THERMOPLASTIC RESINS | REUTER CHEMISCHE APPARATEBAU E.K. (DE) | 2023-03-16 | — | — | WO | disclosed |
| US-8178077-B2 | Drug development target protein and target gene, and method of screening | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20090233274-A1 | DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING | REVERSE PROTEOMICS RESEARCH INSTITUTE CO. (JP) | 2009-09-17 | — | — | US | disclosed |
| CN-1520325-A | Antitumoral formulations of thioxanthenone | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2004-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233274-A1 | DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING | NCS1, PRSS12, TPX2 | ALDH1A1 4286/4885HPGD 3875/4885KDM4E 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.